The serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patientsReport as inadecuate

The serum protein responses to treatment with Xiaoke Pill and Glibenclamide in type 2 diabetes patients - Download this document for free, or read online. Document in PDF available to download.

Clinical Proteomics

, 14:19

First Online: 17 May 2017Received: 14 December 2016Accepted: 06 May 2017DOI: 10.1186-s12014-017-9154-0

Cite this article as: Zhang, X., Sun, H., Paul, S.K. et al. Clin Proteom 2017 14: 19. doi:10.1186-s12014-017-9154-0


AimThe Xiaoke Pill containing Chinese herb extracts and Glibenclamide, is used in therapy for type 2 diabetes mellitus T2DM, and is effective in reducing the risk of hypoglycemia and improving diabetes symptoms compared with Glibenclamide. We describe a quantitative proteomics project to measure the T2DM serum proteome response to the Xiaoke Pill and Glibenclamide.

MethodsBased on a recently conducted 48-week clinical trial comparing the safety and efficacy of Glibenclamide n = 400 and Xiaoke Pill n = 400, after matching for age, sex, BMI, drug dose and whether hypoglycemia occurred, 32 patients were selected for the serum based proteomic analysis and divided into four groups with-without hypoglycemia treated with Xiaoke Pill or Glibenclamide, n = 8 for each group. We screened the differential serum proteins related to treatments and the onset of hypoglycemia using the iTRAQ labeling quantitative proteomics technique. Baseline and follow-up samples were used.

ResultsThe quantitative proteomics experiments demonstrated that 25 and 21 proteins differed upon treatment with the Xiaoke Pill in patients without and with hypoglycemia, respectively, while 24 and 25 proteins differed upon treatment with Glibenclamide in patients without and with hypoglycemia, respectively. The overlap of different proteins between the patients with and without hypoglycemia given the same drug treatment was much greater than between the patients given different drug treatments.

ConclusionsWe conclude that the serum proteins response to the two different anti-diabetic drug treatments may serve as a sensitive biomarker for evaluation of the therapeutic effects and continue investigations into the mechanism.

KeywordsType 2 diabetes mellitus Hypoglycemia Proteomics Glibenclamide Chinese herb AbbreviationsT2DMtype 2 diabetes mellitus

HbA1cglycated hemoglobin

TCMtraditional Chinese medicine

iTRAQisobaric tags for relative and absolute quantitation

MRMmultiple reaction monitoring

FDRfalse discovery rate



Ang IIangiotensin II

HDLhigh density lipoprotein

Electronic supplementary materialThe online version of this article doi:10.1186-s12014-017-9154-0 contains supplementary material, which is available to authorized users.

Xiuying Zhang and Haidan Sun contributed equally to this work

Author: Xiuying Zhang - Haidan Sun - Sanjoy K. Paul - Quanhui Wang - Xiaomin Lou - Guixue Hou - Bo Wen - Linong Ji - Siqi Liu


Related documents